Abiraterone acetate is a steroidal antiandrogen, accurately an androgen amalgam inhibitor, acclimated in aggregate with prednisone in metastatic castration-resistant prostate blight (previously alleged hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate blight not responding to androgen denial or analysis with androgen receptor antagonists. It is a prodrug to the alive abettor abiraterone, and is marketed by Janssen Biotech beneath the barter name Zytiga. In addition, Intas Pharmaceuticals markets the biologic beneath the barter name Abiratas, Cadila Pharmaceuticals markets the biologic as Abretone, and Glenmark Pharmaceuticals as Abirapro.
Abiraterone acetate is adumbrated for use in aggregate with prednisone as a analysis for metastatic castration-resistant prostate cancer. It has accustomed FDA (28 April 2011), EMA , MHRA and TGA approval for this indication. In Australia it is covered by the Pharmaceutical Benefits Scheme if getting acclimated to amusement castration-resistant prostate blight and accustomed in aggregate with prednisone/prednisolone (subject to the altitude that the accommodating is not currently accepting chemotherapy, is either aggressive or antipathetic of docetaxel, has a WHO achievement cachet of <2, and his ache has not back become accelerating back analysis with PBS-subsidised abiraterone acetate has commenced).